Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.

The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...